Enanta is leveraging its early success with its licensed HCV products to become a leader in viral and liver diseases. Enanta’s research and development efforts are currently focused on the following disease targets: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH), hepatitis B virus (HBV), human metapneumovirus (hMPV) and SARS-CoV-2. For an overview of our research, including our licensed products, please see our Pipeline.


RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children under one year of age in the United States. There is currently no effective treatment available for RSV infection.

Enanta’s research in RSV is focused on non-fusion inhibitors that target virus replication. Enanta's lead candidate, EDP-938, an N-protein inhibitor, has been studied in a Phase 2 challenge study with top-line results announced in June 2019. In November 2019, Enanta initiated RSVP, a Phase 2b study in adult outpatients with community-acquired RSV. Learn more.

Enanta Research


The World Health Organization (WHO) has declared that NASH and its precursor, non-alcoholic fatty liver disease (NAFLD) are now the top causes of liver disease in Western countries and represent a major global health concern.

Enanta’s research in NASH is initially focused on EDP-305 and EDP-297. Both are agonists of the Farnesoid X Receptor (FXR). FXR is a nuclear receptor and a main regulator of bile acid levels in the liver and small intestine. Learn more.


Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. It is estimated that 250 million people worldwide are chronically infected, and 15-25% of patients with chronic HBV infection develop chronic liver disease, including cirrhosis, liver cancer, or liver decompensation.

Enanta has selected EDP-514, an inhibitor of the HBV core protein as its first clinical candidate with topline Phase 1 results announced in February 2020. Learn more.


Discovered in 2001, hMPV is in the same paramyxovirus family as RSV. It is the second most common cause of lower respiratory tract infection in children of less than five years of age behind RSV and is associated with greater than 20,000 hospitalizations in the U.S every year. It also presents a significant health challenge in the elderly and immunocompromised individuals with more than 100,000 hospitalizations annually.

Enanta has discovered a series of novel small molecular inhibitors of hMPV with nanomolar EC50 in vitro. These compounds are currently under lead optimization, with the goal of identifying a potential drug candidate for preclinical and clinical proof-of-concept studies. Learn more.


The pandemic coronavirus disease COVID-19 is caused by the infection of a novel human coronavirus, severe acute respiratory syndrome-coronavirus (SARS-CoV-2). This is only the seventh known coronavirus that infects humans. SARS-CoV-2 causes serious infection, manifested by fever and pneumonia, leading to acute respiratory distress syndrome, which has been described in up to 20% of COVID-19 cases.

Enanta is taking a two-pronged approach to its COVID-19 efforts. The company is testing compounds from its existing antiviral compound library for potential activity against SARS-CoV-2, as well as initiating a novel drug discovery program to identify new candidates to treat COVID-19. Learn more.